Niu Huanzhang, Du Tingwei, Xiao Quanping, Hu Xin, Li Dongmin, Wang Chao, Gao Wanqin, Xing Taohong, Xu Xiangmei
Department of Interventional Radiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Oncotarget. 2017 Mar 16;8(33):55593-55599. doi: 10.18632/oncotarget.16286. eCollection 2017 Aug 15.
To investigate the efficacy and safety of transarterial embolization (TAE) using embolization microspheres in the treatment of non-hypervascular malignant liver tumors.
Patients with malignant non-hypervascular liver tumors, who were treated with TAE using embolization microspheres, were selected and analyzed retrospectively. The technical success rate, tumor response, and complications were assessed.
Six patients were included in the study: 1 patient each with hepatocellular-cholangiocarcinoma, intrahepatic cholangiocarcinoma, hepatic metastasis after resection of common bile duct carcinoma, liver metastasis from colon cancer, liver metastasis from esophageal cancer, and liver metastasis from pancreatic cancer. The technical success rate was 100%. At 1 and 3 months after TAE, tumor local reactions were seen in 6/6 and 2/6 patients, respectively, and the tumor necrosis rates were 48%-73% and 22%-68%, respectively. The main complications were those related to the embolization syndrome, including 1 case of liver abscess and 1 case of severe pain on the first day after embolization.
TAE with embolization microspheres is safe and effective in non-hypervascular liver tumors. It is a feasible option for palliative therapy of these tumors.
探讨使用栓塞微球行经动脉栓塞术（TAE）治疗非富血性恶性肝肿瘤的疗效及安全性。
回顾性选取接受使用栓塞微球行TAE治疗的非富血性恶性肝肿瘤患者。评估技术成功率、肿瘤反应及并发症。
本研究纳入6例患者，分别为肝细胞胆管癌、肝内胆管癌、胆总管癌切除术后肝转移、结肠癌肝转移、食管癌肝转移、胰腺癌肝转移各1例。技术成功率为100%。TAE术后1个月和3个月时，分别有6/6例和2/6例患者出现肿瘤局部反应，肿瘤坏死率分别为48% - 73%和22% - 68%。主要并发症为与栓塞综合征相关的并发症，包括1例肝脓肿和1例栓塞术后第1天出现的剧烈疼痛。
使用栓塞微球行TAE治疗非富血性肝肿瘤安全有效。是这些肿瘤姑息治疗的可行选择。
